Intellia sees path to take CRISPR into eye via SparingVision
Rather than building own ophthalmology pipeline, Intellia partners with French biotech for therapies against three targets
Intellia is building on this summer’s early clinical proof-of-concept data for its gene editing platform with an ophthalmology deal with SparingVision, the CRISPR company’s first move into the space.
Intellia Therapeutics Inc. (NASDAQ:NTLA) is licensing rights to its coveted foundational CRISPR-Cas9 IP to SparingVision S.A.S for therapies against three ophthalmology targets in exchange for 10% equity in the preclinical biotech and about $200 million in milestones per program, plus royalties. ...